FINWIRES · TerminalLIVE
FINWIRES

調査速報:パブリックストレージ:売上高とFFOが予想を上回り、第1四半期の既存店舗の純営業利益はプラス成長に転じた

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。PSAは、第1四半期の売上高が12億1,000万ドルとなり、2025年第1四半期の11億8,000万ドルから2.9%増加し、市場予想を700万ドル上回りました。既存店売上高は10億ドルで横ばいとなり、引き続き安定化の兆しが見られました。一方、純営業利益(NOI)は0.4%増の7億3,900万ドルとなり、好転の転換点を示しました。修繕・維持費(-5.8%)とマーケティング費用(-4.5%)の減少が、第1四半期の既存店NOIのプラス成長に大きく貢献し、効果的なコスト管理が実証されました。第1四半期の既存店売上高と純営業利益(NOI)は改善したものの、PSAは2026年度の既存店NOI成長率の見通しを従来通り3.9%減から0.5%減に据え置いた。同社の厳格なコスト管理策は、ポートフォリオ全体の売上高成長が依然として緩やかな水準にとどまる中でも、利益率の拡大を支えているようだ。主要指標における第1四半期の安定化傾向は好ましいものの、経営陣は依然として広範な事業環境に対して適切な慎重姿勢を維持していることが、この見通しの据え置きを示唆していると考えられる。

Related Articles

International

Japan's Unemployment Rate Ticks Up to 2.7% in March

Japan's unemployment rate inched up to 2.7% in March compared with the previous month's 2.6%, according to government data released on Tuesday.The data showed that the number of employed decreased slightly to a seasonally adjusted 68.15 million from 68.27 million in February, while the number of jobless people increased to 1.86 million from 1.85 million the prior month.

$^N225
Asia

Market Chatter: Japan Faces Risk of Missing on New Drugs Due to US Pricing Model

Japan may miss out on breakthrough drugs because a U.S. pricing model threatens to link American drug costs to lower Japanese prices under the most favored nation (MFN) plan, Nikkei reported on Tuesday.Under the plan, the U.S. would reference prices from countries, including Japan, for Medicare and Medicaid, though companies could avoid this by not launching products in Japan, the news daily said.This could lead pharmaceutical firms to delay or skip entering the Japanese market, while Japan might face upward pressure on drug prices and higher social insurance costs, the publication said.Industry groups are urging Japan to reassess its pricing rules to align innovative drug prices with international levels and maintain them during patent periods, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^N225
Asia

Echo IQ Deploys AI-Based Decision Support Software into the US Health System

Echo IQ (ASX:EIQ) deployed EchoSolv AS, its artificial intelligence-based decision support software for the assessment of severe aortic stenosis, into the Mount Sinai Health System in New York, according to a Tuesday filing with the Australian bourse.The company continues to engage with prospective hospitals in the US regarding potential opportunities for the product, the filing said.

$ASX:EIQ